BioCryst Pharmaceuticals BCRX Shares Reserved for Future Issuance Under Stock Plans
Shares Reserved for Future Issuance Under Stock Plans at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CommonStockCapitalSharesReservedForFutureIssuance.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's shares reserved for future issuance under stock plans.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's shares reserved for future issuance under stock plans?
- BioCryst Pharmaceuticals (BCRX) reported shares reserved for future issuance under stock plans of 64.8M in Q1 2026.
- How has BioCryst Pharmaceuticals's shares reserved for future issuance under stock plans changed year-over-year?
- BioCryst Pharmaceuticals's shares reserved for future issuance under stock plans increased by 5.4% year-over-year, from 61.5M to 64.8M.
- What is the long-term trend for BioCryst Pharmaceuticals's shares reserved for future issuance under stock plans?
- Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's shares reserved for future issuance under stock plans has grown at a 0.6% compound annual growth rate (CAGR), from 67.2M to 68.5M.
- What does shares reserved for future issuance under stock plans mean?
- This represents the total number of common shares authorized and set aside for future issuance to employees and directors under equity compensation plans. It provides insight into the potential future dilution of existing shareholders. Investors monitor this to assess the firm's long-term incentive structure.